Best Available Copy



1 Publication number:

0 161 350

1

EUROPEAN PATENT APPLICATION

- Application number: 84116509.5
- 2 Date of fling: 29.11.82

(a) Int. Cl.4: C 07 D 223/16, C 07 C 87/28 // C07C103/78, C07C91/06

- Priority: 27.11.81 US 325249 14.07.82 US 398015 08.10.82 EP 82305381
- Oate of publication of application: 21.11.85
 Bulletin 85/47
- Designated Contracting States: AT BE CH DE FR GB IT
 LI LU NL SE
- Publication number of the earlier application in accordance with Art. 76 EPC: 0080779

- Applicant: SMITHKLINE BECKMAN CORPORATION, P.O. Box 7929 1 Franklin Plaze, Philadelphia Pennsylvania 19101 (US)
- inventor: DeMarinis, Robert Michael, 104 Cedarbrook Road, Ardmore Pennsylvania 19003 (US) Inventor: Hiebie, Jacob Paul, 2107 Mount Vernon Street, Philadelphia Pennsylvania 19130 (US) Inventor: Matthews, William David, 812 Happy Creek Lane, West Chester Pennsylvania 18380 (US)
- Representative: Johnston, Walter Paul et al, Patent
 Department SMITH KLINE & FRENCH LABORATORIES
 LTD Mundells, Welwyn Garden City Hertfordshire
 AL7 1EY (GB)

Process for preparing benzazepines.

The invention provides a process for preparing a compound of formula (I) and pharmaceutically acceptable salts thereof

50 4

where R is lower alkyl of from 1 to 3 carbon atoms or allyl and

X is halogen which comprises cyclising a compound of formula (ii):

0

where R and X are as defined with reference to formula (1) and Y is halogen under Friedel Crafts conditions.

A PROCESS FOR PREPARING BENZAZEPINES


This invention relates to a process for preparing N-substituted 2,3,4,5-tetrahydro-lH-3-benzazepines and intermediates for use in this process.

In our co-pending European Patent Specification No. 0080779 we have disclosed certain benzazepine compounds that are useful as alpha2 antagonists.

10

5

The compounds concerned are compounds of formula (I):-



15

and their pharmaceutically acceptable salts in which

20 R is lower alkyl of from 1 to 3 carbon atoms or allyl; and

X is halogen such as chloro, bromo or fluoro.

25

A particularly preferred compound of formula (I) is one where R is methyl and X is chloro, that is 6-chloro-2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine.

According to the present invention compounds of formula (I) are prepared by cyclising a compound of formula (II):-

where X and R are as previously defined and Y is halogen under Friedel Crafts conditions in the presence of a Lewis acid and thereafter optionally converting the compound of formula (I) so obtained into a pharmaceutically acceptable salt.

The cyclisation step is carried out using a Lewis acid for example aluminium chloride, aluminium bromide, titanium chloride or antimony chloride.

Preferably the catalyst is aluminium chloride.

15

Preferably the reaction is carried out in a melt of aluminium chloride and ammonium chloride at elevated temperature.

The compounds of formula (II) are novel and form a further aspect of the invention.

Accordingly, in a further aspect the invention provides a compound of formula (II) as previously defined.

25

preferably Y is chlorine or bromine, especially
chlorine.

Compounds of formula (II) can in turn be prepared by reacting a compound of formula (III):-

where X and R are as previously defined with a halogenating agent.

Preferably the halogenating agent is phosphorous 5 pentachloride.

The above compounds of formula (III) can be prepared as follows:-

25

35

The terms X and R are as defined above.

According to the above procedure, a halophenyl acetic acid is treated with thionyl chloride followed by an appropriate amino alcohol. The resultant amide is reduced by any well known agent such as, for example, borane.

The pharmaceutically acceptable acid addition salts 30 of compounds of formula (I) can be prepared by methods well known to the art from both inorganic or organic acids, for example: maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, oxalic, propionic, tartaric,

salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, hydrochloric, hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.

5

The following Examples illustrate the invention. The temperatures are in degrees Centigrade.

Example 1

5

10

15

20

25

30

A mixture of 125 g. (0.73 mol) of O-chlorophenylacetic acid, 155 g. (1.3 mol) of thionyl chloride and 2-3 drops of dimethylformamide in 1500 ml. of toluene was stirred at room temperature for three hours. toluene was evaporated under reduced pressure to give an oil which was dissolved in 200 ml. of methylene chloride. This was added dropwise to a solution of 165 g. (2.2 mol) of N-methylamino ethanol in 1 liter of methylene chloride. After addition was complete, the solution was stirred at room temperature for three hours. The organic solution was washed with water, dilute hydrochloric acid and saturated sodium chloride, dried over magnesium sulfate, filtered and evaporated to give 2-chloro-N-(2-hydroxyethyl)-N-methylbenzeneacetamide as a crystalline solid, m.p. 77°.

To 400 ml. of a 1 mol solution of borane in tetrahydrofuran was added dropwise a solution of 43 g. of the above amide in 350 ml. of tetrahydrofuran at a rate sufficient to maintain a gentle reflux. After addition was complete, the solution was refluxed for two hours, cooled in an ice bath and treated carefully with dilute hydrochloric acid to destroy excess borane. majority of the solvent was removed under vacuum and the residue heated on a steam bath for one hour. mixture was diluted with 300 ml. of water and extracted The aqueous layer was made basic with 40% with ether. sodium hydroxide and extracted with ether. The combined basic extracts were washed with water and saturated sodium chloride, dried and evaporated to give 2-[[2-(2chlorophenyl) ethyl] methylamino] ethanol.

A suspension of 36 g. (0.173 mol) of phosphorous pentachloride in 300 ml. of methylene chloride was treated dropwise with a solution of 37 g. (0.173 mol) of the 2-[[2-(2-chlorophenyl)ethyl]methylamino]ethanol in 150 ml. of methylene chloride. After addition was complete, the mixture was refluxed overnight, evaporated to dryness and partitioned between dilute hydrochloric acid and ether. The aqueous layer was made basic with 10% sodium hydroxide and extracted well with ether. ether extracts were washed with water and saturated sodium chloride, dried over magnesium sulfate and filtered. Addition of a saturated solution of ethereal hydrogen chloride gave a solid precipitate which was removed by filtration, washed with ether and dried to give 2-chloro-N-(2-chloroethyl)-N-methylbenzene ethanamine hydrochloride, m.p. 110°.

5

10

15

To a mixture of 41.5 g (0.155 mol) of the above chloro ethanamine hydrochloride and 6.26 g. (0.117 mol) of ammonium chloride was added 41 g. of anhydrous 20 The reaction became homogenous, aluminium chloride. melted and exothermed. It was placed in an oil bath which had been heated to 175° and stirred for thirty An additional 20 g. of aluminium chloride was minutes. added and the mixture heated for another thirty 25 A final 41 g. portion of aluminium chloride minutes. was added and the reaction heated for twenty hours. was cooled to 140° and poured into 3 l. of ice water containing 300 ml. of concentrated hydrochloric acid and stirred for fifteen minutes. Sixty grams of sodium 30 potassium tartrate was added and stirred until solution It was made basic with 40% sodium was effected. hydroxide, extracted twice with ether and the combined extracts washed with water, and saturated sodium chloride, dried and reduced in volume by half. 35 of a solution of saturated ethereal hydrogen chloride

gave a solid precipitate which was collected, washed with ether and dried to give a white solid. Crystallization from methanol-ethyl acetate gave 6-chloro-3-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine hydrochloride, m.p. 268-270°.

Example 2

5

Following the procedure of Example 1 and

substituting 2-[[2-(2-chlorophenyl)ethyl]ethylamino]ethanol and 2-[[2-(2-chlorophenyl)ethyl]allylamino]ethanol for 2-[[2-(2-chlorophenyl)ethyl]methylamino]ethanol yields the following respective products:
6-chloro-3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine and
6-chloro-3-allyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

Claims

A process for preparing a compound of formula
 and pharmaceutically acceptable salts thereof

5 N-R (1)

where R is lower alkyl of from 1 to 3 carbon atoms or allyl and


X is halogen which comprises cyclising a compound of formula (II):

15 CH₂CH₂NCH₂CH₂Y (II)

where R and X are as defined with reference to formula (I) and Y is halogen under Friedel Crafts conditions.

- 2. A process as claimed in claim 1 where the Lewis acid is aluminium chloride.
- 25 3. A process as claimed in claim 1 or claim 2 where Y is chlorine.
 - 4. A process as claimed in claim 3 where the reaction is carried out in a melt of ammonium chloride.

5. A compound of formula (II):-



35

30

where X, R and Y are as defined in claim 1.

- 6. A compound as claimed in claim 5 where Y is chlorine.
- 7. A compound as claimed in claim 5 or claim 6 where X is chlorine and R is methyl.
- 8. A process for preparing a compound of formula

 (II) as defined in claim 5 which comprises reacting a

 compound of formula (III):-

with a halogenating agent.

5

Claims for the designated state AT

A process for preparing a compound of formula
 and pharmaceutically acceptable salts thereof

10

5

where R is lower alkyl of from 1 to 3 carbon atoms or allyl and

X is halogen which comprises cyclising a compound of formula (II):

15

- where R and X are as defined with reference to formula
 (I) and Y is halogen under Friedel Crafts conditions.
 - 2. A process as claimed in claim 1 where the Lewis acid is aluminium chloride.

- 3. A process as claimed in claim 1 or claim 2 where Y is chlorine.
- A process as claimed in claim 3 where the
 reaction is carried out in a melt of ammonium chloride.
 - 5. A process for preparing a compound of formula (II) as defined in claim 5 which comprises reacting a compound of formula (III):-

-9-

with a halogenating agent.



EUROPEAN SEARCH REPORT

016,13,500 Der

EP 84 11 6509

ategory	Citation of document wi	SIDERED TO BE RELEVA th indication, where appropriata,	Relevant to claim	
,	of rele	vant passages	(O CISIM	APPLICATION (Int. Cl.4)
x	GB-A-1 221 324 * Whole document		1-4	C 07 D 223/16 C 07 C 87/28 C 07 C 103/78 C 07 C 91/06
x	EP-A-0 008 405 * Whole document		1-4	
х	CHEMICAL ABSTRAC REGISTRY HANDBOO Section 1965-19; Columbus, Ohio, * Page 578R, 1208-26-0, 1208-28-2 *	OK, Number 71, page 578R,	5-7	
		•		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
				C 07 D 223/00 C 07 C 87/00
				·
	The present search report has b			
	THE HAGUE	Date 2 FmBleton 1985	ALLA	RD M.S.
Y : par doo A : tec	CATEGORY OF CITED DOCU ticularly relevant if taken alone ticularly relevant if combined w current of the same category hnological background n-written disclosure	after the ith another D: docume L: docume	filing date nt cited in the e nt cited for oth	

Carl Zeiss AG 73446 Oberkochen

Fish & Richardson attn.: Mr. Sean Daley 225 Franklin Street BOSTON, MASSACHUSETTS 02110-2804

USA

Division/Dept.: Patent Department

Dr. Thomas Okon Your contact:

Carl Zeiss AG

Carl-Zeiss-Straße 22 73447 Oberkochen

Germany

Phone: +49 07364-20-

Fax: +49 73 64-20-4006

E-mail: t.okon@zeiss.de

RP-P/Oko/ISt Your ref.: Yours of:

Our ref.: P16097WO Date: 21.03.2007

FIRST VIA EMAIL

New Patent Application

Title: "LH-Reduktion für Wafer-Level-Packaging-Designs"

Our File: P16097WO

Dear Sean:

Please find attached a copy of one more invention report: namely E206276 with the title "Projektionsobjektiv mit verringerten wärmeinduzierten Aberrationen" (= Projection objective with reduced heat-induced aberrations).

We ask you to prepare this invention report as an integration to P16097WO. To my best knowledge you worked recently together with Aurelian Dodoc on P16097WO. Please file the next draft of P16097WO with included E206276, to Holger Walter (h.walter@smt.zeiss.com, phone + 49 7364 20 9185) for commentary.

E206276 introduces a parameter Γ which is helpful for quantifying aberrations, which are induced by the energy absorbed by the lens during exposure: "Lens Heating" for short. This Γ is a geometric term which depends only on the design of the projection objective in combination with its aperture. A projection objective with small Γ does not suffer from Lens Heating that much than projection objectives with greater Γ . The idea is to optimize (=minimize) Γ during the design process of the projection objective.

Since the first priority used by P16097WO is 05/05/06 please contact Holger Walter as soon as possible.

Headquarters: 73446 Oberkochen, Germany Phone: +49 73 64 20-0 Fax: +49 73 64 20-68 08

Internet: www.zeiss.de E-mail; info@zeiss.de

Deutsche Bank AG Heidenheim Account 2 125 367 (Bank code 613 700 86) Tilman Todenhöfer S.W.I.F.T.-address: DEUT DE SS 614 Commercial register: Ulm, HRB 501555

VAT REG No: DE 811 119 940

Chairman of the Supervisory: Board of Management: Dr. Dieter Kurz (President & Dr. Hermann Gerlinger Dr. Michael Kaschke

Blatt 2 zum Schreiben vom 13.12.2006

Following the integration of E206276 and discussions with Holger Walter we ask you to forward a copy of the application text to Mr. Ulrich (ulrich@smt.zeiss.com) and Hetterich (w.hetterich@zeiss.de). The text will be reviewed by Mr. Ulrich.

The inventors of E206276 are

- 1. Holger Walter, Albstrasse 29, 73457 Essingen-Lauterburg, Germany
- 2. Ulrich Löring, Freiherr-von-Liebig-Straße 4, 73447 Oberkochen, Germany
- 3. Daniel Krähmer, Birnenweg 2, 73457 Essingen, Germany
- 4. Johannes Zellner, Karl-Krauß-Weg 4, 73430 Aalen, Germany

All employees of Carl Zeiss SMT AG.

The billing address fort this request is:

Carl Zeiss SMT AG c/o Carl Zeiss AG – Patent Department 73446 Oberkochen Germany

Please note that we ask you to inform us if the costs to prepare the application will exced 5000\$.

If you have any question or if you need any further information please do not hesitate to contact us.

Very truly yours, Carl Zeiss AG

i.V. Gnatzig

i.V. Dr. Zell

Encl.:

- Invention report E206276
- Presentation at the patent board ("Patentkomitee") of E206276